In recent years, the therapeutic landscape of T2D has been profoundly transformed by the introduction of glucagon-like receptor agonists (GLP-1 RA), indicated for the treatment of T2D mellitus. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.